Published 4 days ago • loading... • Updated 3 days ago

The Treatment Landscape For Advanced EGFR-Mutant NSCLC

Summary by cancernetwork.com

Panelists discuss how the treatment landscape for EGFR-mutant non–small cell lung cancer has evolved to include 3 viable frontline options (osimertinib alone, osimertinib plus chemotherapy, and amivantamab plus lazertinib), with treatment selection based on patient characteristics, preferences, and physician judgment rather than a strict algorithmic approach.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All

Left

Center

Right

oncnursingnews.com

Reposted by

cancernetwork.com

The Treatment Landscape For Advanced EGFR-Mutant NSCLC

Panelists discuss how the treatment landscape for EGFR-mutant non–small cell lung cancer (NSCLC) has evolved to include 3 viable frontline options (osimertinib alone, osimertinib plus chemotherapy, and amivantamab plus lazertinib), with treatment selection based on patient characteristics, preferences, and physician judgment rather than a strict algorithmic approach.

4 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right